National health plan report card analyzes PCSK9 inhibitor claims for managed care organizations WASHINGTON – The Institute for Patient Access released a new National Health
Rejection is never pleasant. But for the 34,459 patients whose health plans refuse to cover advanced treatment for high cholesterol, it could also be deadly.
White paper addresses current policy issues impacting biosimilars including naming, interchangeability, and labeling and reimbursement policies WASHINGTON – Today the Biologics Prescribers Collaborative (BPC), a project
WASHINGTON – Tomorrow, April 27, the Biologics Prescribers Collaborative (BPC), a project of the Alliance for Patient Access, will host a congressional briefing on Capitol Hill
Congressional briefing will explore naming, interchangeability, and labeling; reimbursement policies and the Biosimilar User Fee Act WASHINGTON – On Thursday, April 27 the Biologics Prescribers Collaborative
Promising clinical trials data has excited patients with cystic fibrosis and their families. But will access barriers dash their hopes for more and better treatment
Institute for Patient Access paper explains value models must serve as tools, not replacements, for physician decision-making WASHINGTON – The Institute for Patient Access released a